Boston Scientific (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire NxThera, a privately-held company based in Maple Grove, Minnesota. NxThera developed and commercialized, in the United States (U.S.) and Europe, the Rezūm® system which is a minimally invasive therapy in a growing category of treatment options for men with symptoms arising from of benign prostatic hyperplasia (BPH).
Twin Cities med-tech company NxThera to be sold to Boston Scientific in $400M deal
Twin Cities med-tech company NxThera Inc. has agreed to be sold to Boston Scientific Corp. in a deal worth up to about $400 million, the companies announced Wednesday. Maple Grove-based NxThera also will spin out a yet-to-be-named startup as part of the deal. The new company will pursue regulatory approval of NxThera’s device as a treatment for prostate cancer, NxThera CEO Bob Paulson said.
